Intravascular large B-cell lymphoma
MONDO:0020324Intravascular large B-cell lymphoma (IVLBCL) is a very rare form of diffuse large B-cell lymphoma characterized by the selective growth of lymphoma cells within the lumina of small blood vessels (especially the capillaries) that most often presents with a wide range of clinical manifestations (as potentially any tissue can be involved), with patients from Western countries more frequently manifesting with neurological and cutaneous symptoms while patients from Asian countries more frequently displaying hepatosplenomegaly and thrombocytopenia. IVLBCL is characterized by an absence of lymphadenopathy, an aggressive clinical course and a poor prognosis.
Also known as: Tappeiner-Pfleger disease, angioendotheliomatosis proliferans systemisata, angiotropic large cell lymphoma, angiotropic lymphoma, intravascular B-cell lymphoma, intravascular large B-cell lymphoma, intravascular lymphomatosis, malignant angioendotheliomatosis
1995 clinical trials for this condition and its sub-types, 4 tagged with Intravascular large B-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New combo therapy aims to extend remission in elderly lymphoma patients
Disease control OngoingThis study is for people aged 75 or older who have been newly diagnosed with certain aggressive types of B-cell lymphoma. It tests whether adding an oral medication (CC-486, or oral azacitidine) to the standard reduced-dose chemotherapy regimen (R-miniCHOP) can help keep the canc…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC